hotspot -WSS

hotspot

author：hotspot 2025-09-27 18:53:49 - browse：31686

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Emergency workers more likely to restrain Black patients: study

focus

WSS

NIH director takes cautious approach to Biden drug pricing priority

eGenesis tests gene

Think you might have Covid

How digital therapeutics firms are pivoting after Pear's bankruptcy

Intarcia’s device

Thermo Fisher plant for manufacturing gene therapies to expand

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

What does generative AI mean for health care? We asked experts

Thermo Fisher plant for manufacturing gene therapies to expand

Duchenne breakthrough therapy leaves behind pioneering families

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Peter Hotez and the public health issue of online harassment

EpiPen alternative approval delay highlights citizen petition issue

Drug repurposing or repositioning? The language matters

Biotech stock slump in 2023: awaiting the turnaround

Supreme Court strikes down use of affirmative action

Test for long Covid? Researchers find new clue in blood samples

entertainment

Prior authorization will have to move faster under new Biden rule

Second xenotransplant done with gene

eGenesis tests gene

Francis Collins on trust in science and how Covid communications failed

Why doctors need education on FDA device approval process

Ukraine and a new approach to mental health in war

focus

hotspot

focus

focus